Cargando…
Commercially available glutenases: a potential hazard in coeliac disease
BACKGROUND: The only treatment for celiac disease (CD) is a gluten-free diet (GFD). However, there is interest among patients in a medical therapy to replace or help with a GFD. Therapies include gluten-degrading enzymes (glutenases). There are glutenases available marketed as dietary supplements th...
Autores principales: | Krishnareddy, Suneeta, Stier, Kenneth, Recanati, Maya, Lebwohl, Benjamin, Green, Peter HR |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424869/ https://www.ncbi.nlm.nih.gov/pubmed/28567117 http://dx.doi.org/10.1177/1756283X17690991 |
Ejemplares similares
-
Antibiotic exposure and the development of coeliac disease: a nationwide case–control study
por: Mårild, Karl, et al.
Publicado: (2013) -
Two waves of coeliac disease incidence in Sweden: a nationwide population-based cohort study from 1990 to 2015
por: Bergman, David, et al.
Publicado: (2022) -
Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus
por: Schiepatti, Annalisa, et al.
Publicado: (2022) -
E40 glutenase detoxification capabilities of residual gluten immunogenic peptides in in vitro gastrointestinal digesta of food matrices made of soft and durum wheat
por: Mamone, Gianfranco, et al.
Publicado: (2022) -
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease
por: Pinto-Sanchez, M. Ines, et al.
Publicado: (2021)